The funny current: Cellular basis for the control of heart rate

Drugs

Volumn 67, Issue SUPPL. 2, 2007, Pages 15-24

  DiFrancesco, Dario ^a   Borer, Jeffrey S ^b  

^a UNIVERSITY OF MILAN   (Italy)

^b WEILL CORNELL MEDICAL CENTER   (United States)

Author keywords

Heart rate; Ivabradine, therapeutic use; Research and development

Indexed keywords

ACETYLCHOLINE; ADRENALIN; ALINIDINE; AMLODIPINE; ATENOLOL; BETA ADRENERGIC RECEPTOR; IVABRADINE; ZATEBRADINE;

CLINICAL TRIAL; DRUG INHIBITION; HEART; HEART RATE; HUMAN; ISCHEMIC HEART DISEASE; KNOWLEDGE; MODULATION; MONOTHERAPY; REVIEW; SINUS NODE; STABLE ANGINA PECTORIS;

ANGINA;

EID: 36148965480     PISSN: 00126667     EISSN: 00126667     Source Type: Journal    
DOI: 10.2165/00003495-200767002-00003     Document Type: Review

References (61)

1. DiFrancesco D. Pacemaker mechanisms in cardiac tissue. Annu Rev Physiol 1993; 55: 455-72
2. Barbuti A, Baruscotti M, DiFrancesco D. The pacemaker current: from basics to the clinics. J Cardiovasc Electrophysiol 2007; 18 (3): 342-7
3. Benetos A, Rudnichi A, Thomas F, et al. Influence of heart rate on mortality in a French population: role of age, gender, and blood pressure. Hypertension 1999; 33 (1): 44-52
4. Chang M, Havlik RJ, Corti MC, et al. Relation of heart rate at rest and mortality in the Women's Health and Aging Study. Am J Cardiol 2003; 92 (11): 1294-9
5. Goldberg RJ, Larson M, Levy D. Factors associated with survival to 75 years of age in middle-aged men and women: the Framingham Study. Arch Intern Med 1996; 156 (5): 505-9
6. Jouven X, Empana JP, Schwartz PJ, et al. Heart-rate profile during exercise as a predictor of sudden death. N Engl J Med 2005; 352 (19): 1951-8
7. Shattock M, Camm JA. Pure heart rate reduction: the If channels from discovery to therapeutic target. Br J Cardiol 2006; 13 (1): 27-35
8. Ferrari R. Selective heart rate reduction: a new approach to the management of angina pectoris. Medicographia 2002; 24: 201-10
9. Diaz A, Bourassa MG, Guertin MC, et al. Long-term prognostic value of resting heart rate in patients with suspected or proven coronary artery disease. Eur Heart J 2005; 26 (10): 967-74
10. Diaz A, Tardif JC. Clinical applications of exclusive heart rate reduction in emergency cardiology. Medicographia 2005; 27: 82-5
11. Fox K, Ferrari R, Tendera M, et al. Rationale and design of a randomized, double-blind, placebo-controlled trial of ivabradine in patients with stable coronary artery disease and left ventricular systolic dysfunction: the morBidity-mortality EvAlUaTion of the I(f) inhibitor ivabradine in patients with coronary disease and left ventricULar dysfunction (BEAUTIFUL) study. Am Heart J 2006; 152 (5): 860-6
12. DiFrancesco D. The pacemaker current (I(f)) plays an important role in regulating SA node pacemaker activity. Cardiovasc Res 1995; 30 (2): 307-8
13. DiFrancesco D. The onset and autonomic regulation of cardiac pacemaker activity: relevance of the f current. Cardiovasc Res 1995; 29 (4): 449-56
14. Brown HF, DiFrancesco D, Noble SJ. How does adrenaline accelerate the heart? Nature 1979; 280 (5719): 235-6
15. Baruscotti M, Bucchi A, DiFrancesco D. Physiology and pharmacology of the cardiac pacemaker ("funny") current. Pharmacol Ther 2005; 107 (1): 59-79
16. Dobrzynski H, Nikolski VP, Sambelashvilli AT, et al. Site of origin and molecular substrate of atrioventricular junctional rhythm in the rabbit heart. Circ Res 2003; 93 (11): 1102-10
17. Munk AA, Adjemian RA, Zhao J, et al. Electrophysiological properties of morphologically distinct cells isolated from the rabbit atrioventricular node. J Physiol 1996; 493: 801-18
18. Shi W, Wymore R, Yu H, et al. Distribution and prevalence of hyperpolarization-activated cation channel (HCN) mRNA expression in cardiac tissues. Circ Res 1999; 85: e1-6
19. Bucchi A, Baruscotti M, Robinson RB, et al. Modulation of rate by autonomic agonists in SAN cells involves changes in diastolic depolarization and the pacemaker current. J Mol Cell Cardiol 2007; 43: 39-48
20. 2+ release sparks atrial pacemaker activity. News Physiol Sci 2001; 16: 101-6
21. DiFrancesco D, Noble D. A model of cardiac electrical activity incorporating ionic pumps and concentration changes. Phil Trans R Soc Lond 1985; 307: 353-98
22. Robinson RB, Siegelbaum SA. Hyperpolarization-activated cation current: form molecules to physiological function. Annu Rev Physiol 2003; 65: 453-80
23. Altomare C, Terragni B, Brioschi C, et al. Heteromeric HCN1-HCN4 channels: a comparison with native pacemaker channels form the rabbit sinoatrial node. J Physiol 2003; 549 (2): 347-59
24. Moroni A, Gorza L, Beltrame M, et al. Hyperpolarization activated cyclic nucleotide-gated channel 1 is a molecular determinant of the cardiac pacemaker current I(f). J Biol Chem 2001; 276 (31): 29233-41
25. Santoro B, Liu DT, Yao H, et al. Identification of a gene encoding a hyperpolarization-activated pacemaker channels of brain. Cell 1998; 93: 717-29
26. DiFrancesco D, Ducouret P, Robinson RB. Muscarinic modulation of cardiac rate at low acetylcholine concentrations. Science 1989; 243: 669-71
27. DiFrancesco D, Tortora P. Direct activation of cardiac pacemaker channels by intracellular cyclic AMP. Nature 1991; 351 (6322): 145-7
28. DiFrancesco D. Sinoatrial If current: a target for specific heart rate reduction. Medicographia 2002; 24: 218-24
29. Ishii T, Takano M, Xie LH, et al. Molecular characterization of the hyperpolarization-activated cation channel in rabbit heart sinoatrial node. J Biol Chem 1999; 274: 12835-9
30. Ludwig A, Zong X, Jeglitsch M, et al. A family of hyperpolarization- activated mammalian cation channels. Nature 1998; 393: 587-91
31. Seifert R, Scholten A, Gauss R, et al. Molecular characterization of a slowly gating human hyperpolarization-activated channel predominately expressed in thalamus, heart, and testis. PNAS 1999; 96: 9391-6
32. Vaccari T, Moroni A, Rocchi M, et al. The human gene encoding coding for HCN2, a pacemaker channel of the heart. Biochim Biophys Acta 1999; 1446: 419-25
33. Fox K. Future perspectives of If inhibition in various cardiac conditions. Eur Heart J 2005; 7 Suppl. H: H33-6
34. DiFrancesco D, Camm JA. Heart rate lowering by specific and selective If current inhibition with ivabradine: a new therapeutic perspective in cardiovascular disease. Drugs 2004; 64 (16): 1757-65
35. Rosen MR, Bucchi A, Robinson RB. If modulation: perspectives in clinical medicine. Eur Heart J 2006; 8 Suppl. D: D3-8
36. Borer JS. Drug insight: If inhibitors as specific heart-rate-reducing agents. Nat Clin Pract Cardiovasc Med 2004; 1 (2): 103-9
37. Sulfi S, Timmis AD. Ivabradine: the first selective sinus node I(f) channel inhibitor in the treatment of stable angina. Int J Clin Pract 2006; 60 (2): 222-8
38. Eisenberg MJ, Brox A, Bestawros A. Calcium channel blockers: an update. Am J Med 2004; 116 (1): 35-43
39. Ravens U, Wettwer E, Hala O. Pharmacological modulation of ion channels and transporters. Cell Calcium 2004; 35 (6): 572-82
40. DiFrancesco D. Serious workings of the funny current. Prog Biophys Mol Biol 2006; 90 (1-3): 13-25
41. Borer JS. Clinical effect of 'pure' heart rate slowing with a prototype If current inhibitor: placebo-controlled experience with ivabradine. Adv Cardiol 2006; 43: 54-64
42. Kobinger W, Lillie C, Pichler L. Cardiovascular actions of N-allyl-clonidine (ST-567), a substance with specific bradycardic action. Eur J Pharmacol 1979; 58: 141-50
43. Kobinger W, Lillie C, Pichler L. N-allyl-derivative of clonidine, a substance with specific bradycardic action at a cardiac site. Naunyn Schmiedebergs Arch Pharmacol 1979; 306: 255-62
44. DiFrancesco D. Some properties of the UL-FS 49 block of the hyperpolarization-activated (If) current in SA node myocytes. Pflugers Arch 1994; 427: 64-70
45. van Bogaert P, Goethals M, Simoens C. Use- and frequencydependent blockade by Ul-FS 49 of the If pacemaker current in sheep cardiac Purkinje fibres. Eur J Pharmacol 1990; 187: 241-56
46. Satoh H, Hashimoto K. Electrophysiological study of alinidine in voltage clamped rabbit sino-atrial node cells. Euro J Pharmacol 1986; 121 (2): 211-9
47. Doerr T, Trautwein W. On the mechanism of the "specific bradycardiac action" of the verapamil derivative UL-FS 49. Naunyn Schmiedebergs Arch Pharmacol 1990; 341 (4): 331-40
48. Millar JS, Williams EM. Pacemaker selectivity: influence on rabbit atria of ionic environment and of alinidine, a possible anion antagonist. Cardiovasc Res 1981; 15 (6): 335-50
49. Aidonidis I, Brachmann J, Rizos I, et al. Electropharmacology of the bradycardic agents alinidine and zatebradine (UL-FS 49) in a conscious canine ventricular arrhythmia model of permanent coronary artery occlusion. Cardiovasc Drugs Ther 1995; 9 (4): 555-63
50. Borer JS. If inhibition as a therapeutic approach in stable angina: experimental and clinical studies. Medicographia 2005; 27: 44-50
51. Frishman WH, Pepine CJ, Weiss RJ, et al. Addition of zatebradine, a direct sinus node inhibitor, provides no greater exercise tolerance benefit in patients with angina taking extended-release nifedipine: results of a multicenter, randomized, double-blind, placebo-controlled, parallel-group study. The Zatebradine Study Group. J Am Coll Cardiol 1995; 26 (2): 305-12
52. Purcell H, Fox K. Selective and specific If inhibition: new perspectives. Medicographia 2005; 27: 51-4
53. Vilaine JP. The discovery of the selective If current inhibitor ivabradine: a new therapeutic approach to ischemic heart disease. Pharmacol Res 2006; 53: 424-34
54. Bucchi A, Baruscotti M, DiFrancesco D. Current-dependent block of rabbit sino-atrial node I(f) channels by ivabradine. J Gen Physiol 2002; 120 (1): 1-13
55. DiFrancesco D. Cardiac pacemaker I(f) current and its inhibition by heart rate-reducing agents. Curr Med Res Opin 2005; 21 (7): 1115-22
56. Bucchi A, Tognati A, Milanesi R, et al. Properties of ivabradine-induced block of HCN1 and HCN4 pacemaker channels. J Physiol 2006; 572 (Pt 2): 335-46
57. Baruscotti M, DiFrancesco D. Pacemaker channels. Ann N Y Acad Sci 2004; 1015: 111-21
58. Borer JS, Fox K, Jaillon P, et al. Antianginal and antiischemic effects of ivabradine, an I(f) inhibitor, in stable angina: a randomized, double-blind, multicentered, placebo-controlled trial. Circulation 2003; 107 (6): 817-23
59. Lopez-Bescos L, Fillpova S, Martoa R. Long-term safety and antianginal efficacy of the If current inhibitor ivabradine in patients with chronic stable angina: a one-year randomised, double-blind, multicentre trial [abstract 876]. Eur Heart J 2004; 25 Suppl.: 138
60. Ruzyllo W, Ford IF, Tendera MT, et al. Anti-anginal and antiischaemic effects of the If current inhibitor ivabradine compared to amlodipine as monotherapies in patients with chronic stable angina. Randomised, controlled, double-blind trial [abstract 878]. Eur Heart J 2004; 25 Suppl.: 138
61. Tardif JC, Ford I, Tendera M, et al. Efficacy of ivabradine, a new selective I(f) inhibitor, compared with atenolol in patients with chronic stable angina. Eur Heart J 2005; 26 (23): 2529-36